Cryoport Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤Q3 revenue $50.2 million, up 14% year over year
- ➤Full-year 2026 revenue guidance raised to $197 million-$199 million
- ➤Adjusted EBITDA $1.1 million, versus negative $0.6 million year over year
- ➤Commercial cell and gene therapy revenue increased 20% year over year
- ➤Supported therapies rose to 23 and clinical trials reached record 788
Expert Statements
Jerrell Shelton, CEO of Cryoport
“Cryoport delivered third quarter revenue of $50.2 million, reflecting continued momentum across our core cell and gene therapy (CGT) business.”
Jerrell Shelton, CEO of Cryoport
“Revenue from commercial CGT clients increased 20% year over year, BioStorage/BioServices revenue expanded 25%, and total Life Sciences Services revenue grew 18%, underscoring the strength of our integrated platform and the growing demand for our solutions.”
Jerrell Shelton, CEO of Cryoport
“These results reflect both the increasing number of patients worldwide receiving CGT treatments and the continued adoption of our end-to-end temperature-controlled supply chain solutions.”
Jerrell Shelton, CEO of Cryoport
“We also achieved 8% year over year growth in Life Sciences Products revenue, supported by MVE Biological Solutions' (MVE) position as the global market leader in cryogenic systems.”
Jerrell Shelton, CEO of Cryoport
“During the quarter, we further strengthened our leadership position within the CGT ecosystem, ending the period supporting 23 commercial therapies and a record of 788 clinical trials worldwide.”
Jerrell Shelton, CEO of Cryoport
“Our integrated platform, disciplined execution, and growing utilization of our Global Supply Chain Center Network continue to enhance scalability and operating leverage, advancing our progress toward sustained profitability.”
Jerrell Shelton, CEO of Cryoport
“This momentum was reflected in our positive adjusted EBITDA of $1.1 million for the quarter, representing another important milestone in our pathway to profitability initiative.”
Jerrell Shelton, CEO of Cryoport
“Our strong year-to-date performance, combined with expanding support of commercial therapies, deepening customer relationships, a robust clinical trial pipeline, and continued demand for MVE's industry-leading products, gives us confidence in our outlook.”
Jerrell Shelton, CEO of Cryoport
“As a result, we are increasing our full-year 2026 revenue guidance to a range of $197 million to $199 million.”
Cryoport Reports Third Quarter 2026 Financial Results PR Newswire
* Third quarter revenue grew 14% year-over-year to $50.2 million * Commercial Cell and Gene Therapy revenue increased 20% year-over-year * Supporting a record 788 global clinical trials and 23 commercially approved cell and gene therapies as of September 30, 2026 * Raises full-year 2026 revenue guidance to $197 million - $199 million NASHVILLE, Tenn., Nov. 5, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2026.
Get started
Create a free account to read the full story.